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Anti-Mycobacterium tuberculosis IgG antibodies may aid in the diagnosis of active M. 23 
tuberculosis disease. We studied whether anti-M. tuberculosis IgG antibodies are 24 
elevated in active M. tuberculosis disease and assessed factors contributing to false 25 
positive and negative results.  A retrospective study of 2,150 individuals tested by the 26 
QuantiFERON-TB Gold In-Tube (QFT-GIT) assay was conducted at University of Utah, 27 
ARUP Laboratories, November 2008 to December 2010. All samples were tested with 28 
the InBios Active TbDetect™anti-TB IgG antibody assay.  Of 1,044 patients with a 29 
positive QFT-GIT, 59 (5.7%) were positive for M. tuberculosis antibodies.  Fourteen of 30 
1,106 (1.3%) with a negative or indeterminate QFT-GIT were positive for M. 31 
tuberculosis antibodies. M. tuberculosis antibody tests were positive in 61.5% with 32 
confirmed active M. tuberculosis disease and other mycobacterial infections.  Over half 33 
of the false negative M. tuberculosis antibody tests occurred in patients  90 years of age. 34 
False positives were seen in 12.9% of autoimmune patients.  The odds ratio of being 35 
positive on the QFT-GIT and the InBios TB IgG assay increased with confirmed M. 36 
tuberculosis disease or highly suspected M. tuberculosis disease and was 86.7 (95% 37 
confidence interval [CI], 34.4-218.5) in these two groups when compared to patients 38 
negative on both tests.  Although anti-M. tuberculosis antibodies can be detected in 39 
patients with active M. tuberculosis disease, caution should be used in patients where 40 
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Tuberculosis remains the leading single microbial illness globally with one third of the 46 
world’s population infected with Mycobacterium tuberculosis complex. In 2009, there 47 
were over 9.4 million new cases and 1.3 million deaths from M. tuberculosis (25).  While 48 
the host’s immune system typically prevents the organism from spreading beyond the 49 
primary site of infection, 5-10% of these latent M. tuberculosis infections progress to 50 
active disease.  Once the disease becomes active it is contagious and lethal with a 51 
mortality rate of greater than 50% in untreated individuals (6). This is in sharp contrast to 52 
the less than 5% mortality rate in regions implementing the World Health Organization’s 53 
(WHO) guidelines for the diagnosis and treatment of M. tuberculosis (directly observed 54 
treatment, short-course; DOTS) (25). Therefore, early diagnosis of active M. tuberculosis 55 
is a crucial step in the success of treatment through rapid isolation of infected individuals 56 
and the early initiation of prophylaxis. 57 
 58 
Anti-M. tuberculosis IgG antibodies have been shown to increase in patients with active 59 
disease (3, 11, 13, 16). While the function of anti-M. tuberculosis antibodies in providing 60 
protective immunity is still under investigation, it has been proposed that they may be 61 
utilized as a diagnostic marker of active disease (1, 2, 7).  In response to this research, 62 
InBios International (Seattle, WA) has developed the Active TbDetect IgG ELISA to 63 
identify IgG antibodies against several immunodominant M. tuberculosis epitopes (2). In 64 
our prior study, we evaluated the Anda-TB IgG, InBios TB IgG assay and the IBL M. 65 
tubercuosis IgG ELISA in a pilot study of 18 patients positive for M. tuberculosis by 66 
culture and/or ADD and 88 healthy U.S.-born individuals who tested negative by 67 
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risk factors for M. tuberculosis infection (2). We found that Anda-TB IgG had a 69 
sensitivity of  83.3% and specificity of 72.0%. The InBios TB IgG assay had a sensitivity 70 
of 83.3% and specificity 98.9%. In that study, we identified an important limitation of the 71 
M. tuberculosis IgG assays in the fact that both the InBios TB IgG assay and the Anda-72 
TB IgG assay were positive in only 3 of 6 HIV patients with positive M. tuberculosis 73 
culture and/or ADD for a sensitivity of only 50%. The InBios TB IgG assay, however, 74 
showed promise as being a more specific assay than the Anda-TB IgG assay, with a 75 
specificity of 98.9%. Therefore, we chose to examine the InBios assay performance 76 
characteristics further in our current study.   77 
 78 
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Study Participants.  Sample collection took place from November 2008 to December 81 
2010 on samples originally sent to ARUP Laboratories (Salt Lake City, UT) for M. 82 
tuberculosis testing on the QFT-GIT assay.  Two-thousand one-hundred and fifty 83 
consecutive samples were collected.  Samples were stored at -70 to -20°C until testing 84 
was performed at which point they were stored at 2 to 4°C until testing was complete.  85 
The protocol used was approved by the institutional review board of the University of 86 
Utah (IRB #40573).   87 
 88 
Following sample collection, histories were obtained through phone interviews with 89 
ordering physicians.  Relevant clinical information was obtained during the interview 90 
process and doctors were fully informed of what information could be released according 91 
to the Health Insurance Portability and Accountability Act (HIPPA) of 1996.  Patient 92 
classifications are listed in Table 1. 93 
 94 
QuantiFERON-TB Gold In-Tube Assay. The QFT-GIT assay was run according to the 95 
manufacturer’s protocol.  Patients had whole blood collected in three separate tubes: a TB 96 
antigen tube containing three M. tuberculosis specific antigens ESAT-6, CFP-10 and 97 
TB7.7, a mitogen tube containing phytohemagglutinin and a nil tube with no stimulants.  98 
Following an incubation of 16 to 24 hours the plasma is separated by centrifugation and 99 
run on an IFN-Ȗ ELISA.  The investigators that performed the QFT-GIT assay were 100 
blinded to the clinical history of the patients.  Patients were considered negative if the 101 
antigen value minus the nil value was less than 0.35 IU/mL.  Patients were considered 102 
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were considered indeterminate if the mitogen value minus the nil value was less than 0.5 104 
IU/mL or if the nil value was greater than 8.0 IU/mL.   105 
 106 
M. tuberculosis IgG Testing.  M. tuberculosis IgG testing was performed on the InBios 107 
Active TbDetect™ IgG ELISA (InBios International, Seattle, WA).  The test was 108 
performed according to the manufacturer’s protocol.  Briefly, serum samples were 109 
incubated in wells containing several M. tuberculosis specific antigens (Mtb81, Mtb8, 110 
Mtb48, DPEP, 38kDa protein, and two additional proprietary antigens).  Following a 111 
conjugate incubation step, substrate was added and a color was developed.  Our previous 112 
study concluded the cutoff of 0.500 optical density (OD) at 450nm (OD450) maximized 113 
sensitivity and specificity (2). The equivocal reference range was defined as 0.425-0.499 114 
optical density at 450nm. First a cutoff was determined by following the manufacturer’s 115 
recommendation as the average OD of normal serum (n=83) + 3 S.D. = 0.450 OD. The 116 
equivocal range was then defined as the cutoff OD of 0.450 ± 5.5% (2). At the time the 117 
InBios TB IgG assay was performed the clinical histories of the patients was unknown.  118 
 119 
Statistical Analysis.  Comparison of the InBios TB IgG assay positivity between the 120 
QFT-GIT positive and the QFT-GIT negative group were analyzed using a Yates’ 121 
corrected Chi-square test.  Odds ratios were calculated comparing the InBios TB IgG 122 
assay positivity rate in QFT-GIT negative samples when compared to each category of 123 
QFT-GIT positive patients.  Statistical analysis was done using MedCalc version 10.6.1.0 124 
(MedCalc Software, Mariakerke, Belgium).  Spreadsheets and additional calculations 125 

















anuscript          




Medical histories were obtained on 876 of the 1044 (83.9%) patients with a positive 128 
QFT-GIT result and on a small subset (70 of 1006; 7.0%) of patients with a negative 129 
QFT-GIT result.  No histories were obtained on any of the 100 patients with QFT-GIT 130 
indeterminate results.  Age and sex information was available for all patients included in 131 
the study.  The QFT-GIT positive patients consisted of 46.3% females with a mean age of 132 
44 years (range <1 year to 97 years).  The QFT-GIT negative patients consisted of 58.0% 133 
females with a mean age of 45 years (range 1 year to 102 years), and the QFT-GIT 134 
indeterminate patients consisted of 50.0% females with a mean age of 47 years (range <1 135 
year to 84 years).  Of the 876 patients with a positive QFT-GIT result and known history, 136 
the WHO region of origin was known on 728 (Table 2). 137 
  138 
Overall, 5.6% of patients positive on the QFT-GIT assay were positive on the InBios TB 139 
IgG assay, while only 1.2% of patients negative on the QFT-GIT assay were positive on 140 
the InBios TB IgG assay (Table 3).  When separated by region, individuals from Africa 141 
and Mexico/Central America had the highest positivity rates on the InBios TB IgG assay 142 
at 9.7% and 9.6%, respectively.  The U.S./Canada region had the most individuals 143 
enrolled (339), where the country of origin was known, and had a positivity rate of 5.3% 144 
(Table 2). 145 
  146 
Patients were classified in terms of disease state and their reactivity on the QFT-GIT 147 
assay.  Each individual’s active M. tuberculosis infection risk status and QFT-GIT result 148 
was then compared with their qualitative InBios TB IgG antibody result (Table 4).  149 
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risk for active M. tuberculosis infection had anti-M. tuberculosis IgG antibody positivity 151 
rates of 3.2%, 10.9% and 43.8%, respectively.  Patients who were positive on the QFT-152 
GIT assay with confirmed active mycobacterial disease had an anti-M. tuberculosis IgG 153 
antibody positivity rate of 61.5%.  Patients who were positive on the QFT-GIT assay and 154 
being screened prior to biological treatment for pre-existing autoimmune disease had an 155 
anti- M. tuberculosis IgG positivity rate of 12.9%. 156 
 157 
Eight out of 13 (61.5%) patients who were positive on the QFT-GIT assay with known 158 
active mycobacterial disease were positive on the InBios TB IgG assay, all with 159 
pulmonary disease (Table 5). Two had infections with non-tuberculous mycobacteria, 160 
Mycobacterium fortuitum and Mycobacterium gordonae. Infections with non-tuberculous 161 
mycobacteria have been known to follow M. tuberculosis infections. However, there was 162 
no information regarding previous M. tuberculosis infection in these two patients.  Five 163 
patients with confirmed active M. tuberculosis infections were QFT-GIT positive, but 164 
negative on the InBios TB IgG antibody assay. Three of the five patients were 90 years of 165 
age or greater. The 4th patient negative by the InBios TB IgG antibody assay was 166 
immunosuppressed. The 5th patient had no history to suggest an explanation for a 167 
negative InBios TB IgG antibody test. 168 
 169 
Seven out of 16 patients with physician suspected active M. tuberculosis  infection were 170 
positive on the InBios TB IgG assay (43.8%) (Table 6). Four of the positive patients had 171 
pulmonary disease. One patient was treated for M. tuberculosis meningoencephalitis in 172 
the past and another was suspected to have ocular M. tuberculosis infection. Nine patients 173 
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assay. Five had pulmonary disease. Two had suspected ocular M. tuberculosis infection. 175 
One had suspected tuberculous peritonitis and another had suspected disseminated M. 176 
tuberculosis infection. 177 
 178 
To measure the relationship between disease status and anti-M. tuberculosis IgG antibody 179 
level odds ratios and 95% confidence intervals (CI) were calculated using the InBios TB 180 
IgG positivity rate amongst disease free individuals (QFT-GIT negative) as an OR of 181 
1.00.  The crude odds ratio for all QFT-GIT positive individuals was 4.91 (95% CI, 2.62 182 
to 9.19).  Odds ratios varied from 2.69 (95% CI, 1.33 to 5·45) in individuals with a low 183 
risk of active disease to 129.47 (95% CI, 36.94 to 453.71) in individuals with confirmed 184 
active disease (Table 4). 185 
 186 
To assess if BCG vaccination status had an effect on the InBios TB status, patients were 187 
further stratified into vaccine status groups and odds ratios were calculated.  The vaccine 188 
status was known on 474 of the 1044 patients who were positive on the QFT-GIT assay.  189 
The crude OR for BCG vaccinated QFT-GIT positive individuals was 2.09 (95% CI, 1.01 190 
to 4.35, P=0.05).  However, when stratified according to active M. tuberculosis infection, 191 
BCG vaccination was never significantly associated with a positive InBios TB IgG result. 192 
 193 
To determine the predictive ability of the quantitative QFT-GIT values to assess active 194 
M. tuberculosis disease, the means within each category of QFT-GIT positive patients 195 
were compared.  Means ranged from a low of 4.24 to a high of 5.28.  There was no 196 
significant difference in QFT-GIT values between risk groups. As the likelihood of active 197 
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of the differences were statistically significant when using the Student’s t-Test to 199 
compare the mean result of each category with the low risk group (Table 7).  Additionally 200 
no correlation was seen when anti-M. tuberculosis IgG results (OD) were compared with 201 
QFT-GIT levels (IU/mL) by scatter plot analysis (linear regression coefficient of 202 
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It has been observed that during active M. tuberculosis disease a humoral response occurs 205 
in the host, which can be measured using anti-M. tuberculosis antibodies.  206 
Immunoglobulin G antibodies directed against several M. tuberculosis antigens have 207 
been proposed as potential markers of tuberculosis of which, Mtb81, Mtb8, Mtb48, DPEP 208 
(MPT32), 38 kDa protein and two proprietary antigens are contained on the InBios TB 209 
IgG assay (2).  Both anti-Mtb81 and anti-MPT32 antibodies have been previously shown 210 
to be highly specific markers of active M. tuberculosis disease; however, individually 211 
they lack sufficient sensitivity (12, 19).  The 38 kDa has been well characterized as an 212 
immunodominant protein present in M. tuberculosis culture filtrates, and although anti-38 213 
kDa antibodies offers good specificity, they suffer from low sensitivity when utilized 214 
alone (4, 9, 19-21). Individually these antibodies may be highly specific, however, used 215 
alone they lack sensitivity due to the heterogeneous antibody response to M. tuberculosis 216 
(4, 15). Therefore, InBios developed their assay with a combination of antigens in an 217 
attempt to maximize sensitivity and specificity. 218 
 219 
Recently, the WHO published a policy statement regarding commercial serodiagnostic 220 
tests for diagnosis of tuberculosis.  Based on a bivariate meta-analysis of commercially 221 
available tests including 67 studies, they concluded that M. tuberculosis antibody tests 222 
not be used for the diagnosis of pulmonary and extra-pulmonary M. tuberculosis 223 
infections (24).  In their summary statement, they stated specifically that the Anda-TB 224 
IgG (the most commonly evaluated test in their study) had a pooled sensitivity of 76% in 225 
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previously published smaller pilot study on M. tuberculosis IgG antibody testing of three 227 
commercial M. tuberculosis antibody ELISAs was included in the WHO analysis (2).  228 
 229 
The present study has identified some additional limitations of the InBios TB-IgG assay 230 
in terms of sensitivity and specificity. Out of 13 individuals with confirmed active 231 
disease, five were negative on the InBios TB-IgG assay.  Three of these five false 232 
negatives were in patients 90 years or older.  The lack of M. tuberculosis antibodies in 233 
these individuals may be due to decreased levels of immunoglobins that can be observed 234 
in immunosenescence.  Several changes in the humoral immune response have been 235 
documented in aging individuals including a decreasing responsiveness to vaccinations 236 
and a loss of previously established protective immunity (10, 17, 22, 23).   This issue 237 
with sensitivity of the assay could be considered a general limitation of all immunoassays 238 
that measure antibodies to antigens, and not necessarily unique to the InBios TB IgG 239 
assay.   240 
 241 
One of the other two false negative patients was undergoing immunosuppression therapy 242 
for a renal transplant, which could potentially cause a false negative result on an antibody 243 
detection based assay due to a decrease in IgG levels (5, 8, 18).  The final patient had no 244 
history that would explain a negative antibody result.  Unfortunately, in our present 245 
study, no patients with suspected or active M. tuberculosis  infection were known to be 246 
co-infected with HIV.  But as demonstrated in our previous study, HIV patients could 247 
potentially be negative with the InBios TB IgG assay due to their immunodeficiency.  We 248 
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immunosenescence due to advanced age, that M. tuberculosis antibody tests should not 250 
be depended upon for screening of active M. tuberculosis disease.  251 
 252 
Only 1.2% of QFT-GIT negative patients and 3.2% of QFT-GIT positive known low risk 253 
patients were positive with the InBios TB IgG assay, indicating a specificity of greater 254 
than 96.8%. However, it should be noted that 12.9% of patients in our study with 255 
autoimmune disease were positive with the InBios TB IgG assay.  Autoantibodies 256 
associated with autoimmune and chronic diseases, especially anti-DNA antibodies and 257 
rheumatoid factors often exhibit polyspecific properties which can cause false positive 258 
results in many ELISAs (14).  These autoantibodies are a likely cause of the false 259 
positives in these autoimmune patients.  260 
 261 
Additional specificity issues with the InBios TB IgG assay were identified concerning 262 
cross-reactivity with other mycobacteria. In the present study, two patients that were 263 
positive with both the InBios TB IgG assay and the QFT-GIT, were culture positive with 264 
Mycobacterium fortuitum and Mycobacterium gordonae. The QFT-GIT assay is known 265 
to only cross-react with three non-tuberculous mycobacteria including Mycobacterium 266 
kansasii, Mycobacterium szulgae and Mycobacterium marinum. Cross-reactions with M. 267 
fortuitum and M. gordonae have not been previously reported with the QFT-GIT.  Cross-268 
reactions with non-tuberculous mycobacteria in the InBios TB IgG assay have not been 269 
previously investigated, except with the Mycobacterium bovis bacillus Calmette-Guérin 270 
(BCG) (2).  Since infections with non-tuberculous mycobacteria can follow M. 271 
tuberculosis infections, it is possible that the InBios TB IgG assay was detecting 272 
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information regarding previous M. tuberculosis infection in these two patients. Further 274 
studies of the InBios TB IgG assay will need to be conducted to examine the potential for 275 
cross-reactivity. 276 
 277 
The InBios TB IgG assay does not appear to cross-react with Mycobacterium bovis 278 
bacillus Calmette-Guérin (BCG). This is in contrast to the Anda-TB IgG assay, which we 279 
found to be highly cross-reactive with BCG in our previous study (2). In the present 280 
study, BCG vaccination was never significantly associated with a positive InBios TB IgG 281 
result. In our previous study we found that only one of 25 (4%) serum samples from 282 
BCG-vaccinated individuals were positive in the InBios TB IgG assay, indicating that the 283 
assay did not significantly cross-react with BCG (2).  In that same study, the Anda-TB 284 
IgG assay detected antibodies in 14 out of the 25 (56.0%) serum samples, indicating a 285 
high degree of cross-reaction in BCG vaccinated individuals.  286 
 287 
Some of the overall limitations of the study include the relatively small number of M. 288 
tuberculosis culture confirmed/ADD cases despite the inclusion of over 2,000 patients in 289 
the study.  However, the inclusion of a high number of patients at low risk for active M. 290 
tuberculosis disease makes the analysis of the specificity of the assay very reliable.  Our 291 
study also had the potential limitation of the possible introduction of bias in the method 292 
of medical history collection via phone interviews. Lastly, an additional limitation was 293 
that there were no children under the age of 16 that had active M. tuberculosis disease in 294 
the study, which limits any conclusions that can be made about the pediatric population 295 
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In conclusion, the InBios TB IgG antibody assay could be added to the current 298 
established methods for diagnosing M. tuberculosis infection with the caveat that false 299 
negatives can occur in immunosuppressed patients or elderly patients.  Additionally, 300 
patients with autoimmune disorders are at risk of having a false positive result from 301 
interference of the assay by autoantibodies.  302 

















anuscript          




This study was supported by the University of Utah, ARUP Institute for Clinical and 305 


















anuscript          





1. Abebe, F., and G. Bjune. 2009. The protective role of antibody responses during 310 
Mycobacterium tuberculosis infection. Clin Exp Immunol 157:235-243. 311 
2. Anderson, B. L., R. J. Welch, and C. M. Litwin. 2008. Assessment of three 312 
commercially available serologic assays for detection of antibodies to 313 
Mycobacterium tuberculosis and identification of active tuberculosis. Clin 314 
Vaccine Immunol 15:1644-1649. 315 
3. Azzurri, A., G. V. Kanaujia, O. Y. Sow, B. Bah, A. Diallo, G. Del Prete, and 316 
M. L. Gennaro. 2006. Serological markers of pulmonary tuberculosis and of 317 
response to anti-tuberculosis treatment in a patient population in Guinea. Int J 318 
Immunopathol Pharmacol 19:199-208. 319 
4. Demkow, U., M. Filewska, D. Michalowska-Mitczuk, J. Kus, J. Jagodzinski, 320 
T. Zielonka, Z. Zwolska, M. Wasik, and E. Rowinska-Zakrzewska. 2007. 321 
Heterogeneity of antibody response to myobacterial antigens in different clinical 322 
manifestations of pulmonary tuberculosis. J Physiol Pharmacol 58 Suppl 5:117-323 
127. 324 
5. Duchini, A., J. A. Goss, S. Karpen, and P. J. Pockros. 2003. Vaccinations for 325 
adult solid-organ transplant recipients: current recommendations and protocols. 326 
Clin Microbiol Rev 16:357-364. 327 
6. Frieden, T. R. 2002. Can tuberculosis be controlled? Int J Epidemiol 31:894-899. 328 
7. Glatman-Freedman, A., and A. Casadevall. 1998. Serum therapy for 329 
tuberculosis revisited: reappraisal of the role of antibody-mediated immunity 330 

















anuscript          
University of Utah Institutional Repository  
Author Manuscript
 18
8. Goldfarb, N. S., R. K. Avery, M. Goormastic, A. C. Mehta, R. Schilz, N. 332 
Smedira, L. Pien, M. T. Haug, S. M. Gordon, L. K. Hague, J. M. Dresing, T. 333 
Evans-Walker, and J. R. Maurer. 2001. Hypogammaglobulinemia in lung 334 
transplant recipients. Transplantation 71:242-246. 335 
9. Greenaway, C., C. Lienhardt, R. Adegbola, P. Brusasca, K. McAdam, and D. 336 
Menzies. 2005. Humoral response to Mycobacterium tuberculosis antigens in 337 
patients with tuberculosis in the Gambia. Int J Tuberc Lung Dis 9:1112-1119. 338 
10. Gruver, A. L., L. L. Hudson, and G. D. Sempowski. 2007. Immunosenescence 339 
of ageing. J Pathol 211:144-156. 340 
11. Gupta, S., N. Shende, A. S. Bhatia, S. Kumar, and B. C. Harinath. 2005. IgG 341 
subclass antibody response to mycobacterial serine protease at different stages of 342 
pulmonary tuberculosis. Med Sci Monit 11:CR585-588. 343 
12. Hendrickson, R. C., J. F. Douglass, L. D. Reynolds, P. D. McNeill, D. Carter, 344 
S. G. Reed, and R. L. Houghton. 2000. Mass spectrometric identification of 345 
mtb81, a novel serological marker for tuberculosis. J Clin Microbiol 38:2354-346 
2361. 347 
13. Hoff, S. T., M. Abebe, P. Ravn, N. Range, W. Malenganisho, D. S. Rodriques, 348 
E. G. Kallas, C. Soborg, T. Mark Doherty, P. Andersen, and K. Weldingh. 349 
2007. Evaluation of Mycobacterium tuberculosis--specific antibody responses in 350 
populations with different levels of exposure from Tanzania, Ethiopia, Brazil, and 351 
Denmark. Clin Infect Dis 45:575-582. 352 
14. Levinson, S. S., and J. J. Miller. 2002. Towards a better understanding of 353 
heterophile (and the like) antibody interference with modern immunoassays. 354 

















anuscript          
University of Utah Institutional Repository  
Author Manuscript
 19
15. Lyashchenko, K., R. Colangeli, M. Houde, H. Al Jahdali, D. Menzies, and M. 356 
L. Gennaro. 1998. Heterogeneous antibody responses in tuberculosis. Infect 357 
Immun 66:3936-3940. 358 
16. Mizusawa, M., M. Kawamura, M. Takamori, T. Kashiyama, A. Fujita, M. 359 
Usuzawa, H. Saitoh, Y. Ashino, I. Yano, and T. Hattori. 2008. Increased 360 
synthesis of anti-tuberculous glycolipid immunoglobulin G (IgG) and IgA with 361 
cavity formation in patients with pulmonary tuberculosis. Clin Vaccine Immunol 362 
15:544-548. 363 
17. Ongradi, J., B. Stercz, V. Kovesdi, and L. Vertes. 2009. Immunosenescence 364 
and vaccination of the elderly, I. Age-related immune impairment. Acta Microbiol 365 
Immunol Hung 56:199-210. 366 
18. Pollock, C. A., J. F. Mahony, L. S. Ibels, R. J. Caterson, D. A. Waugh, J. V. 367 
Wells, and A. G. Sheil. 1989. Immunoglobulin abnormalities in renal transplant 368 
recipients. Transplantation 47:952-956. 369 
19. Samanich, K. M., M. A. Keen, V. D. Vissa, J. D. Harder, J. S. Spencer, J. T. 370 
Belisle, S. Zolla-Pazner, and S. Laal. 2000. Serodiagnostic potential of culture 371 
filtrate antigens of Mycobacterium tuberculosis. Clin Diagn Lab Immunol 7:662-372 
668. 373 
20. Silva, V. M., G. Kanaujia, M. L. Gennaro, and D. Menzies. 2003. Factors 374 
associated with humoral response to ESAT-6, 38 kDa and 14 kDa in patients with 375 
a spectrum of tuberculosis. Int J Tuberc Lung Dis 7:478-484. 376 
21. Steingart, K. R., N. Dendukuri, M. Henry, I. Schiller, P. Nahid, P. C. 377 

















anuscript          
University of Utah Institutional Repository  
Author Manuscript
 20
antigens for serodiagnosis of pulmonary tuberculosis: a meta-analysis. Clin 379 
Vaccine Immunol 16:260-276. 380 
22. Weinberger, B., D. Herndler-Brandstetter, A. Schwanninger, D. Weiskopf, 381 
and B. Grubeck-Loebenstein. 2008. Biology of immune responses to vaccines 382 
in elderly persons. Clin Infect Dis 46:1078-1084. 383 
23. Weksler, M. E., and P. Szabo. 2000. The effect of age on the B-cell repertoire. J 384 
Clin Immunol 20:240-249. 385 
24. WHO. 2011. Commerical serodiagnostic tests for diagnosis of tuberculosis: 386 
policy statement. Report. World Health Organization. 387 































anuscript          
University of Utah Institutional Repository  
Author Manuscript
 21
TABLE 1.  Patient classification schema based on physician interviews. 403 
Risk of Active M. 
tuberculosis (TB) Disease 
(total number of patients) Description 
Low (790) Low active risk patients being screened for TB including 
immigrants, students and healthcare workers. 
Medium (95) Physician suspected TB with not more than one secondary 
symptom. 
High (16) Physician suspected TB with two or more secondary 
symptoms including night sweats, weight loss, fever, 
vomiting, severe cough and unresponsiveness to antibiotics. 
Confirmed (13) Physician diagnosed TB; positive AFB smear, culture or 
amplified direct detection method. 
Autoimmune (33) Patients being screened for TB before biological therapy for 
autoimmune disease. 
________________________________________________________________________ 404 
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TABLE 2.  WHO region of origin distribution for a subset of patients with a known 406 









U.S.A./Canada 344 46.6 5.3 (18) 
Southern Asia/Southeastern 
Asia 
161 22.1 6.3 (10) 
Mexico/Central America 74 10.2 9.6 (7) 
Africa 62 8.5 9.7 (6) 
Central Asia/Eastern 
Asia/Russia 
36 5.0 5.6 (2) 
Western Asia 32 4.4 3.1 (1) 
Europe 14 1.9        7.1 (1)  
Caribbean 5 0.7 40.0 (2) 
Oceania 3 0.4 0 (0) 
South America 2 0.3 0 (0) 
Total 728 100.0 6.5 (47) 
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TABLE 3.  Comparison between the QFT-GIT assay and the InBios TB IgG assay 409 
 InBios TB IgG assay 
 Positive Negative Equivocal Total 
QFT-GIT     
Positive 59 972 13 1044 
Negative 12 971 23 1006 
Indeterminate 2 95 3 100 
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Table 4.  InBios TB IgG positivity rate and odds ratios for each category separated by patient histories.  Equivocal InBios TB IgG and 411 
indeterminate QFT-GIT results were excluded. 412 
 
TB IgG Result 
   
Category Pos Neg Positivity Rate (%) 
Odds Ratio 
(95% Confidence Interval) 
P Value 
QFT-GIT Negative 12 971 1.2 1.0 
Screen 23 691 3.2 2.69 (1.33-5.45) 0·006 
Medium 10 82 10.9 9.87 (4.14-23.53) <0.001 
High 7 9 43.8 62.94 (20.13-196.80) <0.001 
Confirmed 8 5 61.5 129.47 (36.94-453.71) <0.001 
Autoimmune Screen 4 27 12.9 11.99 (3.63-39.58) <0.001 
 413 
  414 
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TABLE 5. Clinical Histories, PPD and TB IgG antibody results of QFT-IT positive 415 
patients with confirmed mycobacterial infections.* 416 














1 36 U.S. ND No POS 2.141 POS POS Culture  TB 
Pulmonary  
2 70 U.S. NEG No POS 1.867 POS POS ADD 
Pulmonary  
3 22 Mexico UN
K 
Yes POS 1.391 POS POS Smear AFB 
Pulmonary  
Cavitary lesions on 
Chest X-ray 
4 79 U.S. POS No POS 1.282 POS POS Culture 
M. fortuitum 
Pulmonary 
5 67 U.S. ND No UNK 0.968 POS POS smear AFB 
TB bronchitis Dx. 
Exp.to active TB 
6 55 India UN
K 
UNK UNK 0.940 POS POS culture  
M. gordonae 
Pulmonary 
7 32 UNK UN
K 
UNK UNK 0.886 POS POS ADD 
Pulmonary 
8 47 Mexico POS Yes UNK 0.565 POS POS Culture TB 
POS smear AFB 
Pulmonary 




node POS AFB, 
POS PCR 
10 90 U.S. ND No POS 0.086 NEG POS smear AFB 
Pulmonary 
11 52 U.S. POS No POS 0.085 NEG POS Culture TB 
POS ADD 
Pulmonary 
12 90 Vietnam ND UNK UNK 0.064 NEG Ankle Aspirate 
POS smear AFB 




*M. tuberculosis (TB), Amplified Direct Detection (ADD), Positive (POS), Negative 418 
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Table 6. Clinical Histories, PPD and TB IgG antibody results of Quantiferon Positive 420 
Patients with Physician suspected TB. 421 















1 70 China POS Yes POS 2.111 POS Chronic cough; Chest X-ray 
suspicious for TB 
2 16 Somalia POS No POS 1.065 POS Pulmonary nodules on Chest X-
ray;no sputum production 
3 55 U.S. ND Yes POS 1.000 POS Bronchiectasis on Chest X-ray; 
possible exposure to active TB 
4 78 U.S. ND No UNK 0·.80 POS Rapid 15 lb weight loss; exposure 
to active TB years ago 
5 51 India POS No UNK 0.692 POS Serpiginous chorioretinitis 
suspicious for ocular TB. 
6 45 U.S. ND No POS 0.940 POS Empyema and necrotizing 
pneumonia on Chest X-ray 
7 40 Mexico POS UNK POS 0.554 POS Treated for TB 
meningoencephalitis in past; new 
onset hematuria 
8 70 Pakistan UNK UNK POS 0.390 NEG Chronic cough; Chest X-ray 
suspicious for TB 
9 64 Mexico POS UNK NEG 0.273 NEG Suspicious for ocular TB 
10 82 U.S. ND No NEG 0.141 NEG Suspected tuberculous peritonitis; 
granulomas on biopsy; 25 lb 
weight loss;  
11 50 U.S. ND No UNK 0.138 NEG Question of disseminated TB; 
numerous cutaneous lesions; 
necrotizing granulomas; AFB 
negative. 
12 61 U.S. ND No UNK 0.103 NEG Treated for TB as a child; 
suspicious for ocular TB 
13 92 U.S. NEG No POS 0.099 NEG Rapid 10 lb weight loss with 
fatigue; Chest CT shows lesions 
consistent with TB. 
14 86 U.S. POS No POS 0.085 NEG Thoracentesis showed 
lymphocytic exudate consistent 
with active TB. End stage renal 
disease 
15 24 Mexico ND Yes POS 0.078 NEG Pulmonary symptoms, cavitary 
lesions on Chest X-ray; negative 
smear for AFB 
16 22 Ethiopia POS UNK POS 0.063 NEG 9 week history of non-productive 
cough; no sputum production 
*M. tuberculosis (TB), Amplified Direct Detection (ADD), Positive (POS), Negative 422 
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TABLE 7.  Mean QuantiFERON-Gold In-Tube Results 424 
Category Mean Result (IU/mL) P value 
Screen 4.27  
Medium 4.24 0.61 
High 4.59 0.75 
Confirmed 5.28 0.37 
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